Ranbaxy's Anti-Malarial Approval Makes It First Indian Firm To Fully Develop An NCE
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - For Ranbaxy Laboratories Ltd., it has been nearly a decade-long bumpy ride to discover and develop its anti-malarial compound, but India's regulator - the Drug Controller General of India - finally granted the company a conditional approval to market the compound